Quentin Kimmerlin

Quentin Kimmerlin

Auto-generated profile, based on publicly available information

Quentin Kimmerlin

Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
MUMarc Usart
Marc Usart
NHNils Hansen
Nils Hansen
JŠJán Štetka
Ján Štetka
TFTiago Almeida Fonseca
Tiago Almeida Fonseca
AGAlexandre Guy
Alexandre Guy
RSRadek C. Skoda
Radek C. Skoda
Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN) driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central role of glutamine in anabolic and catabolic pathways, we examined the effects of pharmacologically inhibiting glutaminolysis, that is, the conversion of glutamine (Gln) to glutamate (Glu), using CB-839, a small molecular inhibitor of the enzyme glutaminase (GLS). We show that CB-839 strongly reduced the mitochondrial respiration rate of bone marrow cells from JAK2-V617F mutant (VF) mice, demonstrating a marked dependence of these cells on Gln-derived ATP production. Consistently, in vivo treatment with CB-839 normalized blood glucose levels, reduced splenomegaly and decreased erythrocytosis in VF mice. These effects were more pronounced when CB-839 was combined with the JAK1/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO, indicating possible synergies when cotargeting different metabolic and oncogenic pathways. Furthermore, we show that the inhibition of glutaminolysis with CB-839 preferentially lowered the proportion of JAK2-mutant hematopoietic stem cells (HSCs). The total number of HSCs was decreased by CB-839, primarily by reducing HSCs in the G1 phase of the cell cycle. CB-839 in combination with ruxolitinib also strongly reduced myelofibrosis at later stages of MPN. In line with the effects shown in mice, proliferation of CD34+ hematopoietic stem and progenitor cells from polycythemia vera patients was inhibited by CB-839 at nanomolar concentrations. These data suggest that inhibiting GLS alone or in combination with inhibitors of glycolysis or JAK2 inhibitors represents an attractive new therapeutic approach to MPN.

24 November 2022 in Blood
Verified
Journal Article
Closed access
PDF file
QKQuentin Kimmerlin
Quentin Kimmerlin
SMSylvie Moog
Sylvie Moog
AYAlexandra Yakusheva
Alexandra Yakusheva
CZCatherine Ziessel
Catherine Ziessel
AEAnita Eckly
Anita Eckly
FLFrançois Lanza
François Lanza
Native circulating blood platelets present with a discoid flat morphology maintained by a submembranous peripheral ring of microtubules, named marginal band. The functional importance of this particular shape is still debated, but it was initially hypothesized to facilitate platelet interaction with the injured vessel wall and to contribute to hemostasis. The importance of the platelet discoid morphology has since been questioned on the absence of clear bleeding tendency in mice lacking the platelet-specific β1-tubulin isotype, which exhibits platelets with a thinner marginal band and an ovoid shape. Here, we generated a mouse model inactivated for β1-tubulin and α4A-tubulin, an α-tubulin isotype strongly enriched in platelets. These mice present with fully spherical platelets completely devoid of a marginal band. In contrast to the single knockouts, the double deletion resulted in a severe bleeding defect in a tail-clipping assay, which was not corrected by increasing the platelet count to normal values by the thrombopoietin-analog romiplostim. In vivo, thrombus formation was almost abolished in a ferric chloride–injury model, with only a thin layer of loosely packed platelets, and mice were protected against death in a model of thromboembolism. In vitro, platelets adhered less efficiently and formed smaller-sized and loosely assembled aggregates when perfused over von Willebrand factor and collagen matrices. In conclusion, this study shows that blood platelets require 2 unique α- and β-tubulin isotypes to acquire their characteristic discoid morphology. Lack of these 2 isotypes has a deleterious effect on flow-dependent aggregate formation and stability, leading to a severe bleeding disorder.

26 October 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
QKQuentin Kimmerlin
Quentin Kimmerlin
ADArnaud Dupuis
Arnaud Dupuis
SBSatish Bodakuntla
Satish Bodakuntla
CWClaire Weber
Claire Weber
VHVéronique Heim
Véronique Heim
FLFrançois Lanza
François Lanza

7 January 2022 in Platelets
Verified
Journal Article
Closed access
QKQuentin Kimmerlin
Quentin Kimmerlin
SMSylvie Moog
Sylvie Moog
CRCatherine Ravanat
Catherine Ravanat
CSCatherine Strassel
Catherine Strassel
FLFrançois Lanza
François Lanza
Glycoprotein V (GPV) is a highly expressed 82 KDa platelet surface transmembrane protein which is loosely attached to the GPIb-IX complex. Despite remaining questions concerning its function, GPV presents several unique features which have repercussions in hematology, atherothrombosis, immunology and transfusion. GPV is specifically expressed in platelets and megakaryocytes and is an ideal marker and reporter gene for the late stages of megakaryopoiesis. The ectodomain of GPV can be released by a number of proteases, namely thrombin, elastase and ADAM10 and 17. Although it was originally proposed as a thrombin receptor, this hypothesis was abandoned since thrombin activation was preserved after blockade of GPV cleavage and in Gp5 knockout mice. The combined potential of GPV to reflect the direct action of thrombin, platelet exposure to strong agonists and inflammatory conditions has led one to evaluate its utility as a marker in the context of atherothrombosis. Increased plasma levels of soluble GPV have notably been recorded in myocardial infarction, stroke and venous thromboembolism. It is also highly valued in transfusion to monitor platelet storage lesions. GPV presents several polymorphisms, which are a possible source of alloantibodies, while autoantibodies have been frequently detected in immune thrombocytopenia. The real biological function of this glycoprotein nevertheless remains an enigma, despite the respectively decreased and increased responses to low concentrations of collagen and thrombin observed in Gp5 knockout mice. Current studies are exploring its role in modulating general or VWF-induced platelet signaling, which could bear relevance in thrombosis and platelet clearance.

11 March 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
MUMarc Usart
Marc Usart
QKQuentin Kimmerlin
Quentin Kimmerlin
JSJan Stetka
Jan Stetka
CSCédric Stoll
Cédric Stoll
SRShivam Rai
Shivam Rai
RSRadek C. Skoda
Radek C. Skoda

14 March 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SMSylvie Moog
Sylvie Moog
LMLéa Mallo
Léa Mallo
AEAnita Eckly
Anita Eckly
CJCarsten Janke
Carsten Janke
APAurora Pujol
Aurora Pujol
QKQuentin Kimmerlin
Quentin Kimmerlin
The functional diversity of microtubules is regulated through the expression of distinct α- and β-tubulin isotypes together with several posttranslational modifications, a concept known as tubulin code. Tubulin detyrosination is a reversible posttranslational modification that consists of the removal of the genetically encoded C-terminal tyrosine residue of most α-tubulins. While this modification has been observed in the megakaryocyte lineage, its importance remains poorly understood in platelet biogenesis. To assess the role of α-tubulin detyrosination in platelet biogenesis. The responsible enzymes and the relative abundance of detyrosinated α-tubulins were monitored by quantitative reverse transcription-polymerase chain reaction and Western blotting, respectively, in human cultured megakaryocytes and platelets differentiated from CD34+ hematopoietic stem and progenitor cells. The function of α-tubulin detyrosination was assessed in human cultured megakaryocytes treated with the VASH-SVBP inhibitor EpoY, and in mice constitutively inactivated for Svbp (which encodes the cofactor of the VASH detyrosinases). Transcriptional analysis identified VASH1-SVBP and MATCAP as the predominant detyrosinases in the megakaryocyte lineage. During megakaryocyte maturation, their transcript levels progressively increased and correlated with the accumulation of detyrosinated α-tubulins. Remarkably, inhibition of VASH1-SVBP by EpoY abolished tubulin detyrosination, establishing VASH1-SVBP as the main functional detyrosinase in megakaryocytes. More importantly, EpoY enhanced proplatelet formation and platelet production in vitro. These in vitro data were confirmed in vivo in SVBP-deficient mice, which exhibited an increase in platelet counts. These findings reveal, for the first time, a role for tubulin detyrosination in proplatelet formation, thereby expanding our understanding of the megakaryocyte tubulin code beyond tubulin isotypes.